



Resolution n°15-2016-e

A randomised trial to compare dolutegravir+darunavir/r versus recommended standard of care antiretroviral regimens in patients with HIV infection who have failed recommended first line therapy

Recalling Resolution n°3-2015-e, in which the UNITAID Board provided its go-ahead for the development by the UNITAID Secretariat of a full draft grant agreement package for the proposed Project “*A randomised trial to compare dolutegravir+darunavir/r versus recommended standard of care antiretroviral regimens in patients with HIV infection who have failed recommended first line therapy*” submitted by The University of New South Wales through the Kirby Institute; and

Noting the alignment of the Project with the Board-approved Area for Intervention: ‘Improving Adult Antiretroviral Therapy in Low and Middle-income Countries: Providing Support for Evidence-gathering on the Use of New Priority Antiretroviral Regimens for First and Second-line Therapy’;

The Board authorizes, subject to availability of funds, the Executive Director to commit up to US\$ 8,806,936 for the Project.

Funding is conditional upon signature of the draft grant agreement between UNITAID and The University of New South Wales.

Lead Organisation: The University of New South Wales

Project Duration: 4 years

A handwritten signature in blue ink, appearing to read "C. Amorim".

Celso Amorim
Chair of the UNITAID Executive Board

Date: *November, 1 2016*